Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Current Leases (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Current Leases for 6 consecutive years, with $5.9 million as the latest value for Q1 2025.

  • On a quarterly basis, Current Leases rose 15.21% to $5.9 million in Q1 2025 year-over-year; TTM through Mar 2025 was $5.9 million, a 15.21% increase, with the full-year FY2024 number at $5.7 million, up 15.37% from a year prior.
  • Current Leases was $5.9 million for Q1 2025 at Relay Therapeutics, up from $5.7 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $5.9 million in Q1 2025 to a low of $1.6 million in Q1 2021.
  • A 5-year average of $4.0 million and a median of $4.6 million in 2023 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: surged 221.32% in 2022, then dropped 15.77% in 2023.
  • Relay Therapeutics' Current Leases stood at $1.8 million in 2021, then surged by 131.89% to $4.3 million in 2022, then grew by 16.09% to $5.0 million in 2023, then grew by 15.37% to $5.7 million in 2024, then increased by 3.54% to $5.9 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Current Leases are $5.9 million (Q1 2025), $5.7 million (Q4 2024), and $5.5 million (Q3 2024).